journal
https://read.qxmd.com/read/32970349/the-national-clinical-trials-network-and-the-cooperative-groups-the-road-not-taken
#1
Richard L Schilsky
No abstract text is available yet for this article.
September 24, 2020: Cancer
https://read.qxmd.com/read/32970346/what-happened-to-the-us-cancer-cooperative-groups-a-status-update-ten-years-after-the-institute-of-medicine-report
#2
REVIEW
Monica M Bertagnolli, Charles D Blanke, Walter J Curran, Douglas S Hawkins, Robert S Mannel, Peter J O'Dwyer, Mitchell D Schnall, Norman Wolmark
The US cancer cooperative groups (cooperative groups) were founded in the 1950s to establish a standing infrastructure to conduct multi-institutional cancer clinical trials. Initially funded almost entirely by the US National Cancer Institute (NCI), over the years, the research conducted by the Cooperative Groups has evolved to meet the demands of cancer clinical research, with a scope now encompassing trials to advance cancer treatment, cancer control, biomarker development and validation, and health services research, with a corresponding broadening of their funding sources...
September 24, 2020: Cancer
https://read.qxmd.com/read/32966668/prognostic-impact-of-t-11-14-in-multiple-myeloma-black-and-white-or-shades-of-gray
#3
EDITORIAL
Rajshekhar Chakraborty, Suzanne Lentzsch
No abstract text is available yet for this article.
September 23, 2020: Cancer
https://read.qxmd.com/read/32966625/african-americans-with-translocation-t-11-14-have-superior-survival-after-autologous-hematopoietic-cell-transplantation-for-multiple-myeloma-in-comparison-with-whites-in-the-united-states
#4
Talha Badar, Parameswaran Hari, Omar Dávila, Raphael Fraser, Baldeep Wirk, Binod Dhakal, Cesar O Freytes, Cesar Rodriguez Valdes, Cindy Lee, David H Vesole, Ehsan Malek, Gerhard C Hildebrandt, Heather Landau, Hemant S Murthy, Hillard M Lazarus, Jesus G Berdeja, Kenneth R Meehan, Melhem Solh, Miguel Angel Diaz, Mohamed A Kharfan-Dabaja, Natalie S Callander, Nosha Farhadfar, Qaiser Bashir, Rammurti T Kamble, Ravi Vij, Reinhold Munker, Robert A Kyle, Saurabh Chhabra, Shahrukh Hashmi, Siddhartha Ganguly, Sundar Jagannath, Taiga Nishihori, Yago Nieto, Shaji Kumar, Nina Shah, Anita D'Souza
BACKGROUND: Multiple myeloma (MM) with the translocation t(11;14) may have inferior outcomes in comparison with other standard-risk MM, and it has been suggested to portend a worse prognosis in African Americans in comparison with Whites. This study used the Center for International Blood and Marrow Transplant Research (CIBMTR) database to examine the impact of t(11;14) on the clinical outcomes of patients with MM of African American and White descent. METHODS: This study evaluated 3538 patients who underwent autologous hematopoietic cell transplantation (autoHCT) for MM from 2008 to 2016 and were reported to the CIBMTR...
September 23, 2020: Cancer
https://read.qxmd.com/read/32965680/age-no-bar-a-cibmtr-analysis-of-elderly-patients-undergoing-autologous-hematopoietic-cell-transplantation-for-multiple-myeloma
#5
Pashna N Munshi, David Vesole, Artur Jurczyszyn, Jan Maciej Zaucha, Andrew St Martin, Omar Davila, Vaibhav Agrawal, Sherif M Badawy, Minoo Battiwalla, Saurabh Chhabra, Edward Copelan, Mohamed A Kharfan-Dabaja, Nosha Farhadfar, Siddhartha Ganguly, Shahrukh Hashmi, Maxwell M Krem, Hillard M Lazarus, Ehsan Malek, Kenneth Meehan, Hemant S Murthy, Taiga Nishihori, Rebecca L Olin, Richard F Olsson, Jeffrey Schriber, Sachiko Seo, Gunjan Shah, Melhem Solh, Jason Tay, Shaji Kumar, Muzaffar H Qazilbash, Nina Shah, Parameswaran N Hari, Anita D'Souza
BACKGROUND: Upfront autologous hematopoietic stem cell transplantation (AHCT) remains an important therapy in the management of patients with multiple myeloma (MM), a disease of older adults. METHODS: The authors investigated the outcomes of AHCT in patients with MM who were aged ≥70 years. The Center for International Blood and Marrow Transplant Research (CIBMTR) database registered 15,999 patients with MM in the United States within 12 months of diagnosis during 2013 through 2017; a total of 2092 patients were aged ≥70 years...
September 23, 2020: Cancer
https://read.qxmd.com/read/32965676/age-is-just-a-number-the-wrong-number
#6
EDITORIAL
Susan Bal, Luciano J Costa
No abstract text is available yet for this article.
September 23, 2020: Cancer
https://read.qxmd.com/read/32964427/suicidality-among-adult-survivors-of-childhood-cancer-a-report-from-the-st-jude-lifetime-cohort-study
#7
Margaret M Lubas, Sedigheh Mirzaei Salehabadi, Jeanette Lavecchia, Nicole M Alberts, Kevin R Krull, Matthew J Ehrhardt, Deokumar Srivastava, Leslie L Robison, Melissa M Hudson, Tara M Brinkman
BACKGROUND: Suicide is a serious public health concern. An increased risk of suicide ideation previously has been reported among survivors of childhood cancer. METHODS: Suicide mortality was assessed for all potentially eligible survivors (those aged ≥18 years who were ≥5 years after their cancer diagnosis; 7312 survivors). Risk factors for acute suicidal ideation were assessed among clinically evaluated survivors (3096 survivors) and the prevalence of acute ideation was compared with that of community controls (429 individuals)...
September 23, 2020: Cancer
https://read.qxmd.com/read/32954493/breast-cancer-treatment-delays-by-socioeconomic-and-health-care-access-latent-classes-in-black-and-white-women
#8
Marc A Emerson, Yvonne M Golightly, Allison E Aiello, Katherine E Reeder-Hayes, Xianming Tan, Ugwuji Maduekwe, Marian Johnson-Thompson, Andrew F Olshan, Melissa A Troester
BACKGROUND: Breast cancer mortality is higher for Black and younger women. This study evaluated 2 possible contributors to disparities-time to treatment and treatment duration-by race and age. METHODS: Among 2841 participants with stage I-III disease in the Carolina Breast Cancer Study, we identified groups of women with similar patterns of socioeconomic status (SES), access to care, and tumor characteristics using latent class analysis. We then evaluated latent classes in association with treatment delay (initiation >60 days after diagnosis) and treatment duration (in quartiles by treatment modality)...
September 21, 2020: Cancer
https://read.qxmd.com/read/32941655/preservation-of-spinal-accessory-and-level-2b-sparing-neck-dissection-the-balance-beyond-oncology-and-functionality
#9
LETTER
Nagarjuna G V Reddy, Abhijeet Singh, Anand Subash
No abstract text is available yet for this article.
September 17, 2020: Cancer
https://read.qxmd.com/read/32941654/reply-to-preservation-of-spinal-accessory-and-level-2b-sparing-neck-dissection-the-balance-beyond-oncology-and-functionality
#10
LETTER
Peter T Dziegielewski, Hadi Seikaly
No abstract text is available yet for this article.
September 17, 2020: Cancer
https://read.qxmd.com/read/32940929/intraoperative-and-early-postoperative-complications-in-postchemotherapy-retroperitoneal-lymphadenectomy-among-patients-with-germ-cell-tumors-using-validated-grading-classifications
#11
Eric C Umbreit, Andrew G McIntosh, Chalairat Suk-Ouichai, Luis A Segarra, Levi C Holland, Bryan M Fellman, Stephen B Williams, Arun Z Thomas, Shi-Ming Tu, Curtis A Pettaway, Louis L Pisters, John F Ward, Christopher G Wood, Jose A Karam
BACKGROUND: Postchemotherapy retroperitoneal lymphadenectomy (PC-RPLND) is an essential, yet potentially morbid, therapy for the management of patients with advanced germ cell tumors. In the current study, the authors sought to define the complication profile of PC-RPLND using validated grading systems for intraoperative adverse events (iAEs) and early postoperative complications. METHODS: Between 2000 and 2018, all patients who underwent PC-RPLND were analyzed for iAEs and early postoperative complications using the Kaafarani and Clavien-Dindo classifications, respectively...
September 17, 2020: Cancer
https://read.qxmd.com/read/32940923/quality-reporting-in-postchemotherapy-retroperitoneal-lymph-node-dissection
#12
EDITORIAL
Siamak Daneshmand
No abstract text is available yet for this article.
September 17, 2020: Cancer
https://read.qxmd.com/read/32931057/association-between-postoperative-complications-and-long-term-oncologic-outcomes-following-total-laryngectomy-10-year-experience-at-md-anderson-cancer-center
#13
Stefanos Boukovalas, Ryan P Goepfert, J Michael Smith, Elise Mecham, Jun Liu, Mark E Zafereo, Edward I Chang, Amy C Hessel, Matthew M Hanasono, Neil D Gross, Peirong Yu, Jan S Lewin, Carol M Lewis, Eduardo M Diaz, Randal S Weber, Jeffrey N Myers, Anaeze C Offodile
BACKGROUND: Postoperative complications are an independent predictor of poor survival across several tumors. However, there is limited literature on the association between postoperative morbidity and long-term survival following total laryngectomy (TL) for cancer. METHODS: We conducted a retrospective review of all TL patients at a single institution from 2008 to 2013. Demographic and clinical data were collected and analyzed, including postsurgical outcomes, which were classified using the Clavien-Dindo system...
September 15, 2020: Cancer
https://read.qxmd.com/read/32931035/clinical-outcomes-of-carbon-ion-radiotherapy-for-patients-with-locoregionally-recurrent-nasopharyngeal-carcinoma
#14
Jiyi Hu, Qingting Huang, Jing Gao, Xiyin Guan, Weixu Hu, Jing Yang, Xianxin Qiu, Mingyuan Chen, Lin Kong, Jiade J Lu
BACKGROUND: Reirradiation for locoregionally recurrent nasopharyngeal carcinoma (LR-NPC) after high-dose radiotherapy (RT) is challenging and usually is associated with poor survival and severe toxicities. Because of its physical and biological advantages over photon-beam RT, carbon-ion RT (CIRT) could be a potential treatment option for patients with LR-NPC. METHODS: Patients with LR-NPC who underwent salvage therapy using CIRT at the Shanghai Proton and Heavy Ion Center between May 2015 and June 2019 were analyzed...
September 15, 2020: Cancer
https://read.qxmd.com/read/32931029/impact-of-adjuvant-trastuzumab-on-locoregional-failure-rates-in-a-randomized-clinical-trial-north-central-cancer-treatment-group-n9831-alliance-study
#15
Carlos E Vargas, Cameron S Thorpe, Amylou C Dueck, Kathleen S Tenner, Nancy E Davidson, Silvana Martino, Thomas M Pisansky, E Shelley Hwang, Michele Y Halyard, Barbara A Pockaj, Edith A Perez
BACKGROUND: The goal of this study was to assess the impact of trastuzumab on locoregional failure. METHODS: The analysis included 2763 patients with HER2-positive (HER2+) breast cancer who were randomly assigned to adjuvant doxorubicin (A), cyclophosphamide (C), paclitaxel (T) and trastuzumab (H) (arm A, AC→T [n = 922]; arm B, AC→T→H [n = 988]; arm C, AC→T+H→H [n = 853]). Radiotherapy was given after AC→T concurrently with H. Radiotherapy was given after lumpectomy (L) or after mastectomy (M) with ≥4 positive lymph nodes but was optional for 1 to 3 positive lymph nodes...
September 15, 2020: Cancer
https://read.qxmd.com/read/32931026/intraperitoneal-chemotherapy-hot-timely-and-relevant
#16
EDITORIAL
Helen J Mackay, Elise C Kohn
No abstract text is available yet for this article.
September 15, 2020: Cancer
https://read.qxmd.com/read/32931024/hyperthermic-intraperitoneal-chemotherapy-in-interval-debulking-surgery-for-advanced-epithelial-ovarian-cancer-a-single-center-real-life-experience
#17
Valentina Ghirardi, Carlo Ronsini, Rita Trozzi, Chiara Di Ilio, Andrea Di Giorgio, Stefano Cianci, Gaetano Draisci, Giovanni Scambia, Anna Fagotti
BACKGROUND: An improvement in survival without increasing perioperative morbidity in patients with advanced epithelial ovarian cancer treated with hyperthermic intraperitoneal chemotherapy (HIPEC) after interval debulking surgery (IDS) has been recently demonstrated in a randomized controlled trial. This study was aimed at assessing the feasibility and perioperative outcomes of the use of HIPEC after IDS at a referral cancer center. METHODS: Over the study period, 149 IDSs were performed...
September 15, 2020: Cancer
https://read.qxmd.com/read/32931022/clinical-trial-design-past-present-and-future-in-the-context-of-big-data-and-precision-medicine
#18
REVIEW
Allen Li, Raymond C Bergan
Clinical trials are fundamental for advances in cancer treatment. The traditional framework of phase 1 to 3 trials is designed for incremental advances between regimens. However, our ability to understand and treat cancer has evolved with the increase in drugs targeting an expanding array of therapeutic targets, the development of progressively comprehensive data sets, and emerging computational analytics, all of which are reshaping our treatment strategies. A more robust linkage between drugs and underlying cancer biology is blurring historical lines that define trials on the basis of cancer type...
September 15, 2020: Cancer
https://read.qxmd.com/read/32926760/response-rate-and-local-recurrence-after-concurrent-immune-checkpoint-therapy-and-radiotherapy-for-non-small-cell-lung-cancer-and-melanoma-brain-metastases
#19
Jack M Qian, Allison M Martin, Kate Martin, Lubna Hammoudeh, Paul J Catalano, F Stephen Hodi, Daniel N Cagney, Daphne A Haas-Kogan, Jonathan D Schoenfeld, Ayal A Aizer
BACKGROUND: Prior literature has suggested synergy between immune checkpoint therapy (ICT) and radiotherapy (RT) for the treatment of brain metastases (BrM), but to the authors' knowledge the optimal timing of therapy to maximize this synergy is unclear. METHODS: A total of 199 patients with melanoma and non-small cell lung cancer with BrM received ICT and RT between 2007 and 2016 at the study institution. To reduce selection biases, individual metastases were included only if they were treated with RT within 90 days of ICT...
September 14, 2020: Cancer
https://read.qxmd.com/read/32926435/genomic-expression-assay-testing-among-american-indian-and-alaska-native-women-with-breast-cancer
#20
Schelomo Marmor, Colleen F Longacre, Ariella M Altman, Jane Y C Hui, Eric H Jensen, Todd M Tuttle
BACKGROUND: Breast cancer is the most common cause of cancer mortality for all women, including American Indian and Alaska Native (AI/AN) women. The use of the 21-gene recurrence score (RS) appears to be predictive of the benefit of chemotherapy for women with estrogen receptor (ER)-positive breast cancer. The objective of the current study was to compare RS testing between AI/AN and non-Hispanic White (NHW) women with breast cancer. METHODS: The Surveillance, Epidemiology, and End Results program was used to identify women with ER-positive breast cancer from 2004 through 2015...
September 14, 2020: Cancer
journal
journal
20067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"